Biocryst Pharmaceuticals Inc

NASDAQ: BCRX
$7.19
-$0.19 (-2.6%)
Closing Price on December 3, 2024

BCRX Stock Chart and Intraday Price

BCRX Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Address 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 1,158.56M USD
Shares Outstanding 206,150,000
Biocryst Pharmaceuticals Inc is a biotechnology firm focused on developing treatments for rare diseases. It offers RAPIVAB, RAPIACTA, and PERAMIFLU, which are brands of peramivir injection for acute influenza, and ORLADEYO, an oral treatment for hereditary angioedema. The company is also working on BCX10013, targeting complement-mediated diseases. Founded in 1986 and based in Durham, North Carolina, Biocryst collaborates with various global institutions and companies to advance its research and development efforts.

BCRX Articles

Prediction: This Will Be the Best-Performing Growth Stock Over the Next 5 Years
These five candidates to be the best-performing growth stock over the next five years include biotech, energy, and software stocks.
Trey Thoelcke
Published:

Tuesday's Top Analyst Upgrades and Downgrades: Adobe, Carvana, DoorDash, Micron Technology, Netflix, Nike, PayPal and More
Tuesday's top analyst upgrades and downgrades included Adobe, Annaly Capital Management, BioCryst Pharmaceuticals, Carvana, DoorDash, Kimco Realty, Micron Technology, Netflix, Nike, PayPal and Zim...
Lee Jackson
Published:

Monday's Top Wall Street Analyst Upgrades and Downgrades: Amazon, Apple, Block, Coinbase, Datadog, Fortinet, Gilead Sciences, Moderna, Nvidia, PayPal, Petrobras and More
Monday's top analyst upgrades and downgrades included Amazon.com, Amgen, Apple, BioCryst Pharmaceuticals, Block, Coinbase Global, Datadog, Fortinet, Gilead Sciences, Intercontinental Exchange,...
Lee Jackson
Published:

Thursday's Top Analyst Upgrades and Downgrades: AIG, Alcoa, Coinbase, Home Depot, Merck, Nvidia, Palo Alto Networks, Occidental Petroleum, Salesforce, Shopify, Sirius XM, Target and More
Thursday's top analyst upgrades and downgrades included Alcoa, American International Group, BioCryst Pharmaceuticals, Coinbase Global, GitLab, Home Depot, Merck, Nvidia, Palo Alto Networks,...
Lee Jackson
Published:

Thursday's Top Analyst Upgrades and Downgrades: Canopy Growth, Cleveland-Cliffs, Datadog, Electronic Arts, Palo Alto Networks, Peloton, Snowflake, SoFi and More
Thursday's top analyst upgrades and downgrades included BioCryst Pharmaceutical, Canopy Growth, Cleveland-Cliffs, Datadog, Electronic Arts, Palo Alto Networks, Peloton Interactive, Snowflake, SoFi...
Lee Jackson
Published:

Huge July Employment Report: Analysts Upgrade or Downgrade Duke Energy, Paramount, Teva Pharmaceutical and More
Friday's additional top analyst upgrades and downgrades included Acadia Pharmaceuticals, BioCryst Pharmaceuticals, Duke Energy, Kellogg, Paramount Global, Rhythm Pharmaceuticals and Teva...
Chris Lange
Published:

Friday's Top Analyst Upgrades Downgrades: Boeing, Disney, Gilead Sciences, IBM, Rivian, Roblox, Visa and More
Friday's top analyst upgrades and downgrades included AppLovin, BioCryst Pharmaceuticals, Boeing, CF Industries, Coupa Software, Crocs, Dutch Bros, DigitalOcean, Gilead Sciences, IBM, International...
Lee Jackson
Published:
Last Updated:

Is Earnings Optimism Enough? Analyst Upgrades and Downgrades: CSX, Gap, Peloton, United Airlines and More
Monday’s additional top analyst upgrades and downgrades included Aptiv, BioCryst Pharmaceuticals, CSX, Gap, Nektar Therapeutics, Progressive, Peloton Interactive, Sirius XM and United Airlines.
Chris Lange
Published:

Monday's Top Analyst Upgrades and Downgrades: Alibaba, AT&T, JetBlue, Nvidia, Pinduoduo, Schlumberger, US Bancorp, Wells Fargo and More
Monday's top analyst upgrades and downgrades included Alibaba, AT&T, Baidu, Bilbili, CommScope, JetBlue Airways, Navient, Nvidia, Pinduoduo, Schlumberger, Sea, State Street, Truist Financial, U.S....
Chris Lange
Published:

Tuesday Afternoon Analyst Upgrades and Downgrades: Exxon Mobil, First Solar, Tesla and More
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Tuesday, including Affirm, BioCryst Pharmaceuticals, Exxon Mobile, First Solar and Tesla.
Chris Lange
Published:

BioCryst, Editas, Groupon, Sunrun, Twitter and More of Monday Afternoon's Analyst Calls
24/7 Wall St. looks at some big analyst calls that we have seen so far on Monday, including BioCryst, Editas, Groupon, Sunrun, Twitter and more.
Chris Lange
Published:

BofA Securities Has 5 Stocks to Buy Under $10 With Massive Upside Potential
Ford, General Electric and these other stocks are likely to survive the current troubles and could very well offer patient investors some huge returns over the next year or so.
Lee Jackson
Published:

Top Analyst Upgrades and Downgrades: AppFolio, BioCryst, Booking, DraftKings, Intuit, L Brands, Peloton, Salesforce, Wells Fargo and More
Tuesday's top analyst upgrades and downgrades included AppFolio, BioCryst Pharmaceuticals, Booking, DraftKings, Intuit, L Brands, Peloton Interactive, Salesforce.com and Wells Fargo.
Jon C. Ogg
Published:

12 Stocks Surging That Could Help Treat or Fight Coronavirus
As with almost all pandemic scares and other national and global issues, some speculative stocks manage to see their shares rise sharply.
Chris Lange
Published:

As Coronavirus Spreads, Sensitive China, US, Global Economies Face Great Risks
The Wuhan Coronavirus has escaped China, with the number of cases and the death toll rising. The economic impact beyond the loss of life and suffering is real in many stocks, sectors and local...
Jon C. Ogg
Published:
Last Updated: